Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Tokuhon to Launch 2 Adhesive NSAIDs in China
January 31, 2011
- Daiichi Sankyo, ArQule Begin PIII Trial of ARQ197
January 31, 2011
- Barclays Revises Alfresa's Business Forecasts Downward
January 31, 2011
- Daiichi Sankyo Healthcare Launches Switch OTC Version of Loxoprofen
January 31, 2011
- Toho HD Starts Operating Joint Venture in China
January 31, 2011
- Japan's 1st Direct OTC Drug Based on Western Herbal Medicine Approved
January 31, 2011
- Nomura Securities Highlights CNS Drugs
January 31, 2011
- EC Calls For Submission of Patent Settlement Agreements
January 31, 2011
- Sales of Ethical Drugs Up 3.8% in November 2010
January 31, 2011
- NIBIO Reports Efficient Generation of Hepatoblasts from iPS Cells
January 31, 2011
- Korosho Withholds Approval of Norspan
January 31, 2011
- Top-Four Generics-Only Firms Expand Production Capacity
January 31, 2011
- PAFSC Committee Recommends Halaven for Approval
January 31, 2011
- TAIYO Pharm. Recalls Two Generics
January 31, 2011
- Dasen to Be Re-designated for Reevaluation
January 31, 2011
- Korosho to Consider Diabetes Treatment Strategy Using Incretin-Related Drugs
January 31, 2011
- Nichi-Iko to Transfer More Long-Listed Original Products to Nichi-Iko sanofi-aventis
January 31, 2011
- AZ Refuses Compromise Proposed by Courts over Iressa Lawsuits
January 31, 2011
- NICE Recommends Aricept for Mild AD as Well
January 31, 2011
- 70% of Women Would Like to Be Vaccinated against Cervical Cancer
January 31, 2011
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…